Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents

被引：8

作者：

Falci, Cristina ^{[1
]}

Dieci, Maria Vittoria ^{[1
,2
]}

Guarneri, Valentina ^{[1
,2
]}

Solda, Caterina ^{[1
]}

Bria, Emilio ^{[3
]}

Tortora, Giampaolo ^{[3
]}

Conte, Pierfranco ^{[1
,2
]}

机构：

[1] Ist Oncol Veneto IRCCS, Div Med Oncol 2, I-35128 Padua, Italy

[2] Univ Padua, Dept Surg Oncol & Gastroenterol, I-35128 Padua, Italy

[3] Univ Verona, Azienda Osped Univ Integrata, I-37124 Verona, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 09期

关键词：

antiangiogenic agent; epithelial ovarian cancer; maintenance; PHASE-III TRIAL; TRIPLE ANGIOKINASE INHIBITOR; SOUTHWEST-ONCOLOGY-GROUP; RANDOMIZED-TRIAL; STAGE-III; 1ST-LINE TREATMENT; PRIMARY PERITONEAL; DOUBLE-BLIND; OPEN-LABEL; BIBF; 1120;

D O I：

10.1586/14737140.2014.922415

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past years, although no increase in the cure rate for advanced epithelial ovarian cancer patients has been achieved, a slow prolongation in patients survival has been observed, thanks to the introduction of effective second line or salvage therapies. Attempts to disease chronicization seem therefore of value in this setting. A major effort has been pursued to establish the role of maintenance therapies for epithelial ovarian cancer patients. Although chemotherapy does not seem to have an effective role, promising results are coming from trials investigating maintenance targeted treatments, especially with antiangiogenic agents or PARP inhibitors for selected patients. The aim of this article is to review current evidences on maintenance therapy for epithelial ovarian cancer and put the results in perspective.

引用

页码：1041 / 1050

页数：10

共 60 条

[1] Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers [J].

Abu-Hejleh, Taher ;

Mezhir, James J. ;

Goodheart, Michael J. ;

Halfdanarson, Thorvardur R. .

CURRENT ONCOLOGY REPORTS, 2012, 14 (04) :277-284

[2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[3] Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance [J].

Alvero, Ayesha B. ;

Chen, Rui ;

Fu, Han-Hsuan ;

Montagna, Michele ;

Schwartz, Peter E. ;

Rutherford, Thomas ;

Silasi, Dan-Arin ;

Steffensen, Karina D. ;

Waldstrom, Marianne ;

Visintin, Irene ;

Mor, Gil .

CELL CYCLE, 2009, 8 (01) :158-166

[4] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[5] Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer [J].

Bapat, SA ;

Mali, AM ;

Koppikar, CB ;

Kurrey, NK .

CANCER RESEARCH, 2005, 65 (08) :3025-3029

[6] A PROSPECTIVE RANDOMIZED COMPARISON OF 6 AND 12 CYCLES OF CYCLOPHOSPHAMIDE, ADRIAMYCIN, AND CISPLATIN IN ADVANCED EPITHELIAL OVARIAN-CANCER - A DANISH OVARIAN STUDY-GROUP TRIAL (DACOVA) [J].

BERTELSEN, K ;

JAKOBSEN, A ;

STROYER, I ;

NIELSEN, K ;

SANDBERG, E ;

ANDERSEN, JE ;

AHRONS, S ;

NYLAND, M ;

PEDERSEN, PH ;

LARSEN, G ;

RASMUSSEN, P ;

KIAER, H ;

BICHEL, P ;

JACOBSEN, M ;

HOLUND, B .

GYNECOLOGIC ONCOLOGY, 1993, 49 (01) :30-36

[7] Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study [J].

Bolis, G ;

Danese, S ;

Tateo, S ;

Rabaiotti, E ;

D'Agostino, G ;

Merisio, C ;

Scarfone, G ;

Polverino, G ;

Parazzini, F .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 :74-78

[8] Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].

Bookman, Michael A. ;

Brady, Mark F. ;

McGuire, William P. ;

Harper, Peter G. ;

Alberts, David S. ;

Friedlander, Michael ;

Colombo, Nicoletta ;

Fowler, Jeffrey M. ;

Argenta, Peter A. ;

De Geest, Koen ;

Mutch, David G. ;

Burger, Robert A. ;

Swart, Ann Marie ;

Trimble, Edward L. ;

Accario-Winslow, Chrisann ;

Roth, Lawrence M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425

[9] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study [J].

Burger, Robert A. ;

Sill, Michael W. ;

Monk, Bradley J. ;

Greer, Benjamin E. ;

Sorosky, Joel I. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5165-5171

[10] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

← 1 2 3 4 5 6 →